Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Zanolimumab, a fully human monoclonal antibody: early results of an ongoing clinical trial in patients with CD4(+) mycosis fungoides (MF) type CTCL(stage IB-IVB) who are refractory or intolerant to targretin and one other standard therapy. Duvic, M., Kim, Y., Korman, N. J., Boh, E., Lerner, A., Heffernan, M. P., Hymes, K. B., Pacheco, T., Elmets, C. A., Lisby, S., Baadsgaard, O. AMER SOC HEMATOLOGY. 2006: 772A
View details for Web of Science ID 000242440003520